

Special Issue

Precision Prevention and Care in Chronic Kidney Disease

Message from the Guest Editors

Over ten percent of the world's population, or nearly 850 million people, suffer from chronic kidney disease (CKD). Many complex determinants contribute to it, and some of them may be appropriately avoided. Early CKD is usually asymptomatic, but could be detected by urinary screening. Care is the key to prolong disease progression in late CKD. However, appropriate CKD care depends on underlying diseases and complication controls. In the past decade, personalized data has been well produced and recorded. A wonderful time to assist in the development of care plans for different people who are at risk of or are suffering from CKD's threats is coming. In this Special Issue, I would like to sincerely invite you to contribute your relevant articles on optimizing CKD prevention and care.

Guest Editors

Dr. Ming-Yen Lin

Dr. Daw-Yang Hwang

Dr. Yihuang Kang

Deadline for manuscript submissions

closed (15 June 2023)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/96446

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

jpm





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).